Cardinal Health
CAH
$202.82
-1.36%
Cardinal Health, Inc. is a major player in the healthcare industry, operating as one of the three leading pharmaceutical wholesalers in the United States, responsible for sourcing and distributing branded, generic, and specialty pharmaceuticals to pharmacies, hospitals, and healthcare providers. The company holds a dominant market position alongside Cencora and McKesson, collectively controlling over 90% of the US pharmaceutical wholesale market, and also supplies medical-surgical products globally. The current investor narrative centers on the company's ability to navigate the complex, low-margin distribution landscape while demonstrating consistent profitability and cash flow generation, as evidenced by recent quarterly results and its ongoing commitment to returning capital to shareholders through dividends.…
CAH
Cardinal Health
$202.82
Related headlines
Investment Opinion: Should I buy CAH Today?
Rating & Thesis: Hold. CAH is a stable, cash-generative defensive holding with limited near-term catalysts for significant outperformance, currently trading at a fair valuation that balances its growth prospects against structural margin constraints. This aligns with the generally bullish but not exuberant analyst sentiment. Supporting Evidence: The primary valuation metric, forward P/E of 17.25x, is reasonable for expected earnings growth, supported by a PEG ratio of 0.30. Revenue growth is robust at 18.42% YoY, but profitability is minimal with a net margin of 0.72%. The investment case is anchored by exceptional TTM free cash flow of $5.5B, enabling a 1.22% dividend (31.65% payout ratio). The stock trades at a deep discount on sales (P/S of 0.18x), reflecting the low-margin model but providing a floor. Risks & Conditions: The two biggest risks are further margin erosion from its already thin 1.08% operating margin and a failure to meet forward EPS estimates, triggering multiple compression. This Hold would upgrade to a Buy if the forward P/E compressed below 15x on sustained cash flow, or if the company demonstrated sequential margin expansion above 1.2%. It would downgrade to Sell if revenue growth decelerated below 10% YoY or if quarterly net income fell below $400M. The stock is fairly valued relative to its history and the defensive, low-growth profile it presents.
Sign up to view all
CAH 12-Month Price Forecast
CAH presents a classic 'steady Eddie' profile: a defensive, cash-cow business with a near-monopoly position but virtually no operating leverage. The 12-month outlook is one of range-bound trading, with the base case (60% probability) of meeting EPS estimates and trading between $200-$225 being most likely. The bullish case requires an unlikely breakout in profitability, while the bearish case is mitigated by the stock's deep value on sales and cash flow. The stance would upgrade to Bullish on evidence of sustainable margin expansion above 1.2% or a drop in the forward P/E below 15x without a corresponding drop in earnings outlook. It would turn Bearish if quarterly revenue growth decelerates sharply below 5%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cardinal Health's 12-month outlook, with a consensus price target around $263.67 and implied upside of +30.0% versus the current price.
Average Target
$263.67
12 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
12
covering this stock
Price Range
$162 - $264
Analyst target range
Cardinal Health is covered by 12 analysts, indicating solid institutional research interest. The consensus sentiment leans bullish, with recent institutional ratings showing a preponderance of 'Overweight,' 'Outperform,' and 'Buy' recommendations, including an upgrade from Citigroup from Neutral to Buy in January 2026. The average target price is not explicitly provided in the data, but analyst estimates focus on an average EPS of $17.37 for the coming period, with a range between $17.02 and $17.89, and revenue estimates averaging $378.2 billion. Without a specific price target, the implied upside cannot be calculated, but the consistent positive ratings suggest analysts see fundamental strength or value at current levels. The target range for estimated EPS is relatively tight, with a high of $17.89 and a low of $17.02, representing a spread of only about 5%. This narrow range indicates strong analyst conviction and agreement on the company's near-term earnings trajectory. The high-end estimate likely assumes successful execution on cost initiatives and stable pharmaceutical pricing, while the low-end may factor in potential margin pressure or competitive challenges. The pattern of recent ratings shows stability, with most firms reaffirming their positive stances following earnings reports, and no downgrades are visible in the recent data. This consistent, bullish analyst coverage, combined with the stock's defensive profile and dividend yield of 1.22%, supports a view of Cardinal Health as a core holding for investors seeking exposure to the essential healthcare supply chain with moderate growth expectations.
Bulls vs Bears: CAH Investment Factors
The evidence tilts slightly bullish, grounded in CAH's defensive cash generation, scale, and reasonable forward valuation, which outweigh concerns over its microscopic margins and recent price weakness. The most critical tension in the investment debate is whether the company's robust free cash flow and defensive characteristics can sustainably support its valuation (forward P/E of 17.25x) in the face of virtually non-existent operating leverage and margin expansion potential. The resolution of this tension—specifically, the company's ability to maintain or slightly grow its slim profits amidst cost pressures—will determine if the stock reverts to its uptrend or remains range-bound.
Bullish
- Strong Revenue Growth & Scale: Q2 FY2026 revenue grew 18.42% YoY to $65.44B, demonstrating robust demand and market share in the essential pharmaceutical distribution sector. The company's immense scale, with over 90% market share alongside two peers, provides a durable competitive moat and a stable revenue base.
- Exceptional Free Cash Flow Generation: The company generated $5.5B in TTM free cash flow, supporting a sustainable 1.22% dividend yield and share repurchases. A Price-to-Cash-Flow ratio of 16.89x is reasonable for a defensive cash generator, underpinning shareholder returns.
- Defensive Low-Beta Profile: With a beta of 0.65, CAH is 35% less volatile than the broader market, offering relative stability and downside protection. This aligns with its role as a core, non-discretionary healthcare infrastructure holding, attractive in uncertain economic climates.
- Analyst Conviction & Forward Earnings Growth: Covered by 12 analysts with a bullish consensus, and a tight EPS estimate range ($17.02-$17.89) indicates strong conviction. The forward P/E of 17.25x, a 33% discount to the trailing P/E of 25.94x, implies the market expects significant earnings growth.
Bearish
- Extremely Low & Volatile Margins: Gross margin of 3.38% and operating margin of 1.08% in Q2 FY2026 highlight the razor-thin, competitive nature of distribution. These margins have shown quarterly volatility (e.g., gross margin was 3.86% in Q3 FY2025), making earnings highly sensitive to minor cost pressures.
- Negative Shareholder Equity & Distorted Ratios: Negative shareholder equity results in a Debt-to-Equity ratio of -3.36 and a Return on Equity of -56.13%, complicating traditional financial health assessment. While driven by buybacks and accounting, it signals a leveraged capital structure reliant on consistent cash flow.
- Recent Technical Weakness & Underperformance: The stock is down 5.42% over the past month and has underperformed the SPY by -14.12%, signaling a breakdown from its 52-week high of $233.60. Trading at 85% of its 52-week range suggests the uptrend has stalled, requiring a catalyst to resume.
- High Trailing P/E Relative to History: A trailing P/E of 25.94x is above its recent historical range (e.g., 20.75x in Q1 FY2026), indicating limited multiple expansion potential. The stock must deliver on forward earnings growth expectations to justify its current valuation plateau.
CAH Technical Analysis
The stock is in a sustained uptrend over the past year, evidenced by a robust 47.12% one-year price change, but is currently experiencing a pullback from recent highs. As of the latest close at $199.85, the price is trading at approximately 85% of its 52-week range ($134.76 to $233.60), indicating it has retreated meaningfully from the peak but remains well above the low, suggesting a consolidation phase within a longer-term bullish structure. Recent momentum has turned negative, with the stock down 5.42% over the past month and 4.07% over the past three months, diverging from the strong yearly performance and signaling a potential short-term correction or profit-taking phase. This deceleration is further highlighted by a negative relative strength of -14.12 against the SPY over one month, indicating significant underperformance in the near term. Key technical support is anchored at the 52-week low of $134.76, while immediate overhead resistance sits at the 52-week high of $233.60. A decisive break above the $233.60 resistance would signal a resumption of the primary uptrend, whereas a breakdown below the recent trading range could test lower support levels. The stock exhibits a beta of 0.65, indicating it is 35% less volatile than the broader market (SPY), which is characteristic of a defensive healthcare distribution business and implies lower systematic risk but also potentially muted upside during strong market rallies. This low beta, combined with a current price 14.5% below the 52-week high, presents a scenario where the stock may offer relative stability during market downturns but requires a fundamental catalyst to regain its upward trajectory. The price action shows a clear pattern: a sharp rally from late October 2025 through February 2026, followed by a consolidation and recent decline into April 2026. The 6-month price change of 23.45% remains positive but is being eroded by the recent sell-off. Volume data shows an average of approximately 1.4 million shares traded, but without a significant spike on the recent decline, suggesting the pullback is not driven by panic selling. The stock's positioning, coupled with its low volatility profile, suggests it is in a phase of digesting its prior gains, with the path of least resistance dependent on upcoming fundamental results and broader market sentiment towards defensive sectors.
Beta
0.65
0.65x market volatility
Max Drawdown
-13.1%
Largest decline past year
52-Week Range
$137-$234
Price range past year
Annual Return
+45.0%
Cumulative gain past year
| Period | CAH Return | S&P 500 |
|---|---|---|
| 1m | -1.7% | +12.6% |
| 3m | -4.0% | +2.5% |
| 6m | +6.3% | +4.3% |
| 1y | +45.0% | +28.4% |
| ytd | -1.4% | +4.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CAH Fundamental Analysis
Cardinal Health's revenue trajectory shows robust growth, with Q2 FY2026 revenue reaching $65.44 billion, representing a significant 18.42% year-over-year increase. This growth is part of a multi-quarter acceleration, as revenue has climbed sequentially from $54.88 billion in Q3 FY2025 to the current level, primarily driven by its massive Pharmaceutical segment, which generated $60.67 billion in the latest period. The company's scale in pharmaceutical distribution provides a stable, high-volume revenue base, though growth in this low-margin business is heavily tied to drug price inflation and volume trends in the healthcare sector. The Medical segment (GMPD and Other) contributed approximately $4.98 billion, indicating the Pharmaceutical business is the unequivocal growth engine, albeit with razor-thin margins. The company is profitable, reporting net income of $471 million for Q2 FY2026, translating to a net margin of 0.72%. However, profitability metrics reveal the challenging nature of the distribution business, with a gross margin of 3.38% and an operating margin of 1.08% for the quarter. Margins have shown some quarterly volatility but have generally remained in a tight, low band, characteristic of the industry; for instance, gross margin was 3.63% in the prior quarter (Q1 FY2026) and 3.86% in Q3 FY2025. The key takeaway is that while absolute profits are substantial due to immense scale, margin expansion is limited, and the investment case hinges on efficient execution and cost control to preserve already slim profits. The balance sheet and cash flow picture is mixed but ultimately supportive. The company generated substantial free cash flow of $5.506 billion on a trailing twelve-month basis and reported operating cash flow of $686 million for Q2 FY2026. However, financial health is complicated by a negative shareholder equity position, leading to a Debt-to-Equity ratio of -3.36 and a Return on Equity of -56.13%, which are distorted by accounting treatments like share buybacks and accumulated deficits. More traditional liquidity metrics show a current ratio of 0.94, indicating adequate but not excessive short-term liquidity. The strong free cash flow generation, evidenced by a Price-to-Cash-Flow ratio of 16.89, allows the company to fund dividends (payout ratio of 31.65%) and share repurchases while managing its debt load, reducing reliance on external financing for operations.
Quarterly Revenue
$65.4B
2025-12
Revenue YoY Growth
+0.18%
YoY Comparison
Gross Margin
+0.03%
Latest Quarter
Free Cash Flow
$5.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CAH Overvalued?
Given Cardinal Health's positive net income of $471 million in its latest quarter, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 25.94x and a forward PE of 17.25x based on estimated earnings. The significant gap between the trailing and forward multiples implies the market expects substantial earnings growth, with the forward PE discount of approximately 33% pricing in an anticipated profit recovery or expansion from current levels. Compared to sector averages, Cardinal Health's valuation presents a complex picture. Its trailing PE of 25.94x is above what might be typical for a low-margin distribution business, but this must be contextualized by its growth and cash flow. The Price-to-Sales ratio is exceptionally low at 0.18x, and the EV-to-Sales is 0.22x, reflecting the company's massive revenue base against its market capitalization. The EV-to-EBITDA of 14.80x provides a cleaner picture of operating performance relative to enterprise value. The low multiples on sales and EBITDA suggest the market is not assigning a premium for top-line growth but is valuing the underlying cash-generative operations, which is reasonable given the industry's structural characteristics. Historically, the stock's current trailing PE of 25.94x sits above its own recent historical range observed in the provided data, where it has fluctuated between approximately 14x and 42x over the past several quarters. For instance, it was at 20.75x in Q1 FY2026 and 42x in Q4 FY2025. Trading near the higher end of its recent historical band suggests the market has already priced in a relatively optimistic outlook for earnings stability or improvement. This positioning indicates limited multiple expansion potential from current levels unless the company can deliver sustained margin improvement or growth surprises that justify a permanently higher valuation plateau.
PE
25.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -450x~73x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks stem from the company's ultra-thin and volatile profitability. With a gross margin of just 3.38% and an operating margin of 1.08%, even minor cost inflation or competitive pricing pressure can disproportionately impact net income, which was a modest 0.72% of revenue last quarter. The balance sheet shows negative shareholder equity, distorting ratios like a -56.13% ROE, and while strong cash flow mitigates this, a current ratio of 0.94 indicates limited liquidity cushion for unexpected obligations. Revenue concentration is extreme, with the Pharmaceutical segment comprising 93% of sales, tying the company's fate to the dynamics of drug distribution. Market & Competitive Risks include valuation compression, as the trailing P/E of 25.94x is above its own recent historical average, leaving little room for error. The stock's low beta of 0.65, while defensive, also suggests muted upside during broad market rallies, as evidenced by its recent 14.12% underperformance vs. the SPY over one month. The oligopolistic market structure with Cencora and McKesson offers stability but also caps market share gains and invites regulatory scrutiny on pricing and competition. Sector rotation away from defensive names in a risk-on environment could further dampen interest. Worst-Case Scenario involves a perfect storm of margin compression from renewed competitive intensity or regulatory drug pricing reforms, coupled with a slowdown in healthcare volume growth. This could trigger earnings misses, leading to analyst downgrades and multiple contraction. The realistic downside could see the stock re-testing its 52-week low of $134.76, which represents a potential loss of approximately -33% from the current price of $199.85. A more immediate bear-case target could be the lower end of the recent trading range, around $180, implying a -10% decline.
FAQ
The key risks are, in order of severity: 1) Financial: Extreme sensitivity of net income (0.72% margin) to cost pressures or pricing competition. 2) Operational: Overwhelming revenue concentration (93%) in the low-margin pharmaceutical distribution segment. 3) Macro/Valuation: The stock's recent underperformance (-14% vs. SPY in 1 month) and elevated trailing P/E (25.94x) create vulnerability to further multiple compression. 4) Structural: The leveraged balance sheet, evidenced by negative shareholder equity and a Debt-to-Equity ratio of -3.36, though mitigated by strong cash flow.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $200 and $225, as it meets analyst EPS estimates of ~$17.37 and maintains its current valuation. The Bull Case (25% probability) targets $233-$250, driven by margin improvement and defensive rotation. The Bear Case (15% probability) warns of a drop to $135-$180 on an earnings miss and multiple contraction. The Base Case is most likely, predicated on the assumption that the company's stable cash flows and market position prevent a severe downturn while margin constraints cap the upside.
CAH is fairly valued. Its forward P/E of 17.25x implies the market expects earnings to grow into the multiple from a low base, which is reasonable. The stock is deeply undervalued on a sales basis (P/S of 0.18x), but this correctly reflects its low-margin business model. Compared to its own recent history, the trailing P/E of 25.94x is at the higher end of its range, suggesting limited multiple expansion potential. Overall, the valuation implies the market expects steady execution but no major profitability breakthroughs.
CAH is a good buy for a specific investor profile: those seeking a defensive, low-volatility holding with a reliable dividend, funded by robust cash flow, and who are comfortable with minimal earnings growth potential. With a forward P/E of 17.25x and a 1.22% yield, it offers fair, not compelling, value. The biggest downside risk is margin compression from its already thin 1.08% operating margin. It is not a good buy for growth-oriented investors or those seeking significant capital appreciation in the near term.
CAH is primarily suitable for a long-term (3+ year) investment horizon. Its low beta (0.65) and dividend make it a poor candidate for short-term trading, as it lacks the volatility and catalyst-driven price swings traders seek. For long-term investors, it serves as a stable, cash-generative component of a portfolio, providing defensive exposure and income. The suggested minimum holding period is aligned with a full business cycle to capture the benefits of its consistent capital return, making it ideal for buy-and-hold strategies rather than tactical plays.
